Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial-Reference-Cited by-同舟云学术

Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

Published:2021-05 Issue: Volume:148 Page:382-394
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pérez-García José M.,Llombart-Cussac Antonio,Gion María,Curigliano Giuseppe^ORCID,López-Miranda Elena,Alonso José L.^ORCID,Bermejo Begoña,Calvo Lourdes^ORCID,Carañana Vicente,de. la Cruz Sánchez Susana,Márquez Vázquez Raúl,Prat Aleix^ORCID,Ruiz Borrego Manuel,Sampayo-Cordero Miguel,Seguí-Palmer Miguel Á.^ORCID,Soberino Jesus,Malfettone Andrea,Schmid Peter,Cortés Javier^ORCID

Funder

Merck Sharp and Dohme Ltd

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer;Rugo;Clin Cancer Res,2018

2. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer;Turner;Lancet,2017

3. Annual hazard rates of recurrence for breast cancer during 24 Years of follow-up: results from the International breast cancer study group trials I to V;Colleoni;J Clin Oncol,2016

4. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study;Cortes;Lancet,2011

5. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane;Kaufman;J Clin Oncol,2015

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis;International Immunopharmacology;2024-05

2. Expert consensus on the clinical application of immunotherapy in breast cancer: 2024;Translational Breast Cancer Research;2024-04

3. Experimental and clinical evidence in favour of an effective immune stimulation in ER-positive, endocrine-dependent metastatic breast cancer;Frontiers in Immunology;2024-01-25

4. Profiling the gut and oral microbiota of hormone-receptor positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin;2024-01-09

5. Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial;Journal for ImmunoTherapy of Cancer;2024-01